| Document |
Document Title |
|
WO/2024/088183A1 |
Provided herein are compounds which exhibit activity in the inhibition of RNA polymerase as well as pharmaceutical compositions comprising these compounds and methods of treatment of viral infections by administration of these compounds ...
|
|
WO/2024/049312A3 |
The first object of the invention is a method for the synthesis and purification of a nucleotide and/or a nucleoside. The second object of the invention is a modified nucleoside and/or a nucleotide, being a mono-, di- or triphosphate, co...
|
|
WO/2024/064701A3 |
The disclosure provides adenosine analogs for the treatment of disease such as pain and inflammatory conditions.
|
|
WO/2024/088184A1 |
Provided herein are compounds which exhibit antiviral activity against feline coronavirus and methods of treatment of feline coronavirus infections by administration of these compounds or the pharmaceutical compositions comprising the same.
|
|
WO/2024/083746A1 |
The invention pertains to methods for the synthesis of oligonucleotides using pseudo solid-phase protecting groups, wherein said method comprises at least one aqueous extraction carried out in the presence of one or more amide solvents S...
|
|
WO/2024/084025A1 |
The invention pertains to a method for producing a plant cell comprising a modified RNA molecule, comprising the steps of i) providing the plant cell; and ii) introducing the modified RNA molecule into the plant cell. The modified RNA mo...
|
|
WO/2024/086592A2 |
Disclosed are halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections. Such viral infections can i...
|
|
WO/2024/086312A1 |
The present disclosure provides enhanced nicotinamide adenine dinucleotide (NAD+) compositions and pharmaceutical formulations, useful in the treatment of disorders and diseases regulated by deficiencies in NAD+, and methods of preparati...
|
|
WO/2024/081308A1 |
The present disclosure discloses compositions comprising maribavir, methods of providing the same, and compositions providing intermediates useful in providing maribavir.
|
|
WO/2024/077410A1 |
The present application relates to the technical field of metal ion chemistry, and provides a method for reducing an azide methoxy group, a sequencing method, and a kit. The method for reducing an azide methoxy group provided by the pres...
|
|
WO/2024/076951A2 |
The application provides compounds of Formula (I) as further defined herein, pharmaceutical compositions comprising said compounds, and methods of using said compounds and compositions for the treatment and/or prevention of various viral...
|
|
WO/2024/076915A1 |
Compounds, compositions, and methods useful for treating a viral infection, such as human immunodeficiency virus (HIV) infection, are disclosed. In particular, 4'-thionucleoside analogues and methods for their preparation and use as ther...
|
|
WO/2024/064701A2 |
The disclosure provides adenosine analogs for the treatment of disease such as pain and inflammatory conditions.
|
|
WO/2024/062413A1 |
The present disclosure includes oligonucleotides and nucleic acid compositions having stabilized phosphate moieties. Formula (Ia) and Formula (Ib), wherein: X is selected from a 3- to 5-membered cycloalkyl, -CHCH-, a 3- to 5-membered het...
|
|
WO/2024/059609A1 |
The present disclosure relates to pharmaceutical forms of a CD73 inhibitor, polymorphic forms of the pharmaceutical forms, pharmaceutical compositions comprising the pharmaceutical forms, and methods of treating subjects having cancer by...
|
|
WO/2024/059703A1 |
Provided herein are engineered terminal deoxynucleotidyl transferase (TdT) proteins with certain modifications, including mutations to confer thermal stability and to install an exposed amino acid residue to which a small molecule can be...
|
|
WO/2024/055758A1 |
The present invention relates to the technical field of biological medicines. Disclosed are a cyclic dinucleotide metal compound, and a preparation method therefor and a use thereof. The structural formula of the compound is [M(cyclic di...
|
|
WO/2024/059258A1 |
Click-labeled uridine bases, nucleosides, and phosphoramidites are provided, including improved methods of synthesis, oligonucleotides comprising the click-labeled nucleosides, methods of synthesizing spin-labeled oligonucleotides using ...
|
|
WO/2024/054997A1 |
Provided herein are methods to treat rhegmatogenous retinal detachment (RRD) and/or improve visual outcomes of RRD.
|
|
WO/2024/051696A1 |
The present invention relates to a compound for RNA capping and use thereof and belongs to the technical field of genetic engineering. The compound has a structure represented by formula I. The compound is used for capping an mRNA5' end,...
|
|
WO/2024/050267A1 |
The present disclosure is directed to oligonucleotide dendrons comprising an oligonucleotide stem linked to one or more oligonucleotide branches. The disclosure also provides methods of using the oligonucleotide dendrons.
|
|
WO/2024/049312A2 |
The first object of the invention is a method for the synthesis and purification of a nucleotide and/or a nucleoside. The second object of the invention is a modified nucleoside and/or a nucleotide, being a mono-, di- or triphosphate, co...
|
|
WO/2023/007019A9 |
The present invention is inter alia concerned with (A) a compound of formula (I) as defined herein or a salt, stereoisomer, tautomer or deuterated version thereof, (B) a cap analog comprising a 5' terminal acyclonucleoside, wherein the a...
|
|
WO/2024/040768A1 |
Disclosed in the present invention are a 5-pyridine-1H-indazole compound, a pharmaceutical composition, and a use. The structure of the compound is represented by formula I or II, and also comprised are an isomer or pharmaceutically acce...
|
|
WO/2024/032718A1 |
The present invention relates to a crystal form of a hepatitis C inhibitor and the use thereof in a drug, and specifically relates to a crystal form A of a compound as represented by formula (I), a pharmaceutical composition of the cryst...
|
|
WO/2024/034644A1 |
The present invention provides a compound for treating or preventing reduced intracellular ATP levels. The present invention relates to a compound represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof, and...
|
|
WO/2024/028729A1 |
The present disclosure relates to processes for the fluorination of molecules. One aspect provides a process for incorporating a fluorine atom into a molecule, said process comprising converting a compound of formula X—SG into a compou...
|
|
WO/2024/029877A1 |
The present invention provides novel purine derivative compounds as A3 adenosine receptor agonists, hydrates thereof, solvates thereof, or pharmaceutically acceptable salts thereof. The novel purine derivatives of the present invention h...
|
|
WO/2024/024766A1 |
The purpose of the present invention is to provide an alkylating agent that can alkylate a hydroxyl group at 2' position of a synthetic intermediate for an amidite compound in the presence of a base. The present invention provides an alk...
|
|
WO/2024/017375A1 |
A cyclic substituted compound for RNA capping and use thereof, belonging to the technical field of genetic engineering. The compound has a structure represented by formula (VI). The compound is used for capping an mRNA 5' end, such that ...
|
|
WO/2024/016639A1 |
Provided are a preparation of an anti-viral-infection compound, a method, a compound of formula (I), and a method and intermediate for synthesizing the compound of formula (I). The compound can inhibit the replication of SARS-CoV-2 and c...
|
|
WO/2024/019137A1 |
The present invention relates to a production method of an oligonucleotide that includes a step for condensing, in the presence of an activator, a compound represented by formula (2) [wherein: G2 represents a protecting group of the hydr...
|
|
WO/2024/014770A1 |
The present application relates to a modified RNA for preparing a mRNA vaccine and therapeutic agent, the modified RNA, according to one aspect, comprising a specific chemical modification and genetic modification and thus being capable ...
|
|
WO/2024/012126A1 |
Disclosed in the present invention is a cordycepin-derivatized compound with an anti-tumor effect, which has a structure as represented by formula I. The cordycepin derivative and a pharmaceutical composition thereof provided in the pres...
|
|
WO/2024/013349A1 |
The inventors have now succeeded in developing compounds of Formula (I), described below, having the advantage of inhibiting NAD kinases, in particular P. aeruginosa NADK (PaNADK) enzyme, Listeria monocytogenes (LmNADK) enzyme and/or hum...
|
|
WO/2024/007068A1 |
A process for extracting TTX from biological material containing TTX, wherein the process comprises steps of extracting with a first solvent, concentrating, washing with a second solvent, concentrating again and purifying by chromatography.
|
|
WO/2024/010810A2 |
The disclosure provides conjugates including an Fc domain monomer or Fc domain covalently linked to a moiety that binds to or inhibits CD73. The disclosure also provides pharmaceutical compositions including such conjugates and uses of s...
|
|
WO/2024/002112A1 |
The present invention relates to use of a compound represented by formula (I) in resisting feline coronavirus or calicivirus infection. The compound represented by formula (I) efficiently inhibits the replication of feline coronavirus or...
|
|
WO/2024/002045A1 |
Provided is an oligonucleotide delivery agent comprising at least one lipid moiety comprising at least one linear alkyl group or linear alkylenyl group directly or indirectly conjugated to a single-stranded oligonucleotide, which can be ...
|
|
WO/2024/006376A1 |
The disclosure provides solid forms, e.g. salts and polymorphs, of the compound of Formula (I) and uses thereof. Also provided are the methods of making the solid forms and pharmaceutical formulations comprising the solid forms.
|
|
WO/2024/006461A1 |
The present disclosure relates to solid forms (e.g. crystalline forms, solvates, and crystalline forms thereof) of a compound which is ((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-
5-cyano-3,4-dihydroxytetrahydrofuran-2-yl...
|
|
WO/2024/002007A1 |
The present invention provides a double-stranded RNA comprising a nucleotide analog. The double-stranded RNA of the present invention exhibits one or more of enhanced stability, reduced off-target toxicity, and enhanced effectiveness.
|
|
WO/2024/006953A2 |
The present disclosure relates to monomers and methods for synthesisizing modified oligonucleotides.
|
|
WO/2023/249888A1 |
A composition that includes a micro-RNA mimic containing one or more cytosine nucleosides in which at least one cytosine nucleoside is replaced by cytosine arabinoside. Also provided is a method for killing a cancer cell by contacting it...
|
|
WO/2023/250015A1 |
The present disclosure provides pyrimidine nucleoside compounds, including torcitabine, thymidine, deoxyuridine, deoxycytidine and uridine, and methods to treat telomere biology disorders (TBDs) and aging-related diseases, including hema...
|
|
WO/2023/246860A1 |
The present invention provides an initially capped oligonucleotide primer, a method for preparing same, and use thereof, and particularly, provides an initially capped oligonucleotide primer comprising a hexose ring, a morpholine ring or...
|
|
WO/2023/245040A1 |
Compounds, methods, and compositions for treating or preventing viral infections using flexible nucleosides analogs. The fleximer and reverse fleximer nucleoside analogues having increased flexibility and ability to alter their conformat...
|
|
WO/2023/241699A1 |
The present disclosure relates to a cyclopentyl adenosine derivative and a pharmaceutical use thereof. Specifically, the present disclosure provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, whe...
|
|
WO/2023/245037A1 |
The disclosure provides processes for preparing the compound of formula (VIa-1) and pharmaceutically acceptable salts thereof. Intermediates useful in preparing the compound of formula (VIa-1) are also provided.
|
|
WO/2023/241587A1 |
The present invention provides an oligonucleotide having a cyclic phosphonate modification. The oligonucleotide of the present invention exhibits one or more among enhanced stability, reduced off-target toxicity, and enhanced effectiveness.
|
